cyclic heptapeptide is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-02-11. Numbers and descriptions here follow the published literature rather than marketing material.
Melanotan II is a synthetic peptide analog modeled on alpha-melanocyte-stimulating hormone, a naturally occurring signaling peptide involved in pigmentation. Its structure is a cyclic heptapeptide containing two non-natural substitutions, norleucine at position four and D-phenylalanine at position seven. These modifications resist enzymatic breakdown and extend the molecule's activity relative to the native hormone. The compound binds melanocortin receptors and is studied mainly as a pharmacological tool rather than a therapeutic product. It has never received approval as a medicine in any major jurisdiction.
The compound was developed in the late 1980s and 1990s by academic researchers investigating photoprotection. The rationale held that stimulating melanin production might reduce ultraviolet damage to skin and lower skin cancer risk. Early work examined receptor binding, pigment response, and short-term tolerability in small studies. That program did not produce an approved drug, and formal development stalled after early-phase trials. Whether induced pigmentation confers meaningful photoprotection remains an open question.
Melanotan II is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its structure substitutes a lactam bridge between side chains to increase stability relative to the native hormone. The compound is also known by the shorthand MT-II and by several non-proprietary synonyms used in research catalogues. It is not an approved therapeutic product in any major jurisdiction; material sold under this name is typically offered as a laboratory reagent rather than as a medicine.
Activity is attributed to agonism at melanocortin receptors, particularly MC1R and MC4R. Activation of MC1R on melanocytes increases melanin synthesis, which underlies the reported tanning effect. MC4R engagement in the central nervous system is linked to appetite suppression and to effects on sexual arousal reported in early clinical studies. Those studies were small and were not designed to establish efficacy or long-term safety. Receptor selectivity among the melanocortin subtypes is not absolute, which complicates attribution of any effect to a single pathway.
Regulatory treatment varies between countries. Several national medicines agencies have classified the peptide as unapproved, and customs authorities in some jurisdictions seize shipments on that basis. A few jurisdictions channel supply through prescription-only frameworks that do not list the substance by name. Because the material circulates mainly through online vendors, composition and purity are rarely verified before sale. Surveys of unapproved peptide products have reported labels that did not match measured content in a substantial fraction of samples.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic cyclic heptapeptide | Belongs to the melanocortin agonist family |
| Key substitutions | Nle4 and D-Phe7 | Improve resistance to enzymatic degradation |
| Molecular formula | C50H69N15O9 | Approximately 1024 g/mol |
| Regulatory status | Not approved as a medicine | Distributed as a research chemical |
| Common synonyms | Melanotan II, MT-II, MT-2 | Spelling varies across sources |
Melanotan-2 is a synthetic cyclic heptapeptide designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous tridecapeptide that regulates pigment production. Two modifications distinguish it from the natural hormone: norleucine replaces methionine at the N-terminus, which limits oxidation, and a D-phenylalanine substitution raises receptor affinity. The ring is closed through an aspartate-lysine lactam bridge, giving the molecule a constrained conformation. The free base has a molecular mass near 1024 daltons, and commercial material is usually supplied as an acetate salt. It appears in the literature as a research peptide rather than an approved therapeutic agent.
Receptor studies place melanotan-2 among non-selective melanocortin agonists, binding MC1R, MC3R, MC4R and MC5R rather than a single subtype. Activation of MC1R on cutaneous melanocytes raises tyrosinase activity and shifts pigment synthesis toward eumelanin, which is darker and more photostable than pheomelanin. Central receptors, particularly MC4R, are associated with appetite suppression and with reported effects on sexual function. Because subtype selectivity is low, the same molecule engages pigment, metabolic and vascular pathways at once, and this breadth is a common explanation offered for the range of adverse events described in user reports.
Melanotan II is a synthetic cyclic heptapeptide that acts as an agonist at melanocortin receptors. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous peptide involved in pigment production. The analogue carries a lactam bridge that constrains the ring and slows enzymatic breakdown relative to the native hormone. In research literature it appears under several abbreviations, and naming conventions are not fully standardized. Published descriptions usually place it within the broader melanocortin agonist family.
Receptor binding at MC1R on melanocytes raises intracellular cyclic AMP and increases expression of tyrosinase and related enzymes. The downstream result is greater synthesis of eumelanin, the dark pigment, without ultraviolet exposure acting as the trigger. The compound is not selective, however, and also engages MC3R, MC4R and MC5R, which are expressed in the central nervous system and elsewhere. That lack of selectivity is the explanation usually offered for effects reported outside pigmentation, including appetite suppression and nausea. Selectivity remains a central theme in comparative studies of related peptides.
At 10 Downing Street in early September 1964, impasse developed between Douglas-Home and Smith over the best way to measure black public opinion in Southern Rhodesia. A key plank of Britain's Southern Rhodesia policy was that the terms for independence had to be "acceptable to the people of the country as a whole"—agreeing to this, Smith suggested that white and urban black opinion could be gauged through a general referendum of registered voters, and that rural black views could be obtained at a national indaba (tribal conference) of chiefs and headmen. Douglas-Home told Smith that although this proposal satisfied him personally, he could not accept it as he did not believe the Commonwealth, the United Nations or the Labour Party would also do so. He stressed that such a move towards accommodation with Smith might hurt the Conservatives' chances in the British general election the next month, and suggested that it might be in Smith's best interests to wait until after the election to continue negotiations. Smith accepted this argument. Douglas-Home assured Smith that a Conservative government would settle with him and grant independence within a year. Attempting to form a viable white opposition to the Rhodesian Front, the UFP resurrected itself around Welensky, renamed itself the Rhodesia Party, and entered the Arundel and Avondale by-elections that had been called for 1 October 1964.
=== Age-related changes === Aging affects multiple layers of the eyelid, leading to skin laxity, weakening of the orbital septum, fat herniation, and volume loss. These changes contribute to upper eyelid hooding and lower eyelid contour irregularities.
=== Nausea === Diphenhydramine also has antiemetic properties, which makes it useful in treating the nausea that occurs in vertigo and motion sickness. However, when taken above the recommended doses, it can cause nausea (especially above 200 mg). Diphenhydramine is the active ingredient in Dramamine, aka Gravol.
Sources: en.wikipedia.org
Public health analysts have remarked that the debate over the origins of SARS-CoV-2 is fueling unnecessary confrontation, resulting in bullying and harassment of scientists, and is deepening existing geopolitical tensions and hindering collaboration at a time where such mutual cooperation is required, both to deal with the current pandemic and in preparation for future such outbreaks. This comes in the face of scientists having predicted such events for decades: according to Katie Woolaston, researcher at the Queensland University of Technology, "The environmental drivers of pandemics are not being widely discussed". The debate comes at a moment of difficult global relations with Chinese authorities. Researchers have noted that the politicisation of the debate is making the process more difficult, and that words are often twisted to become "fodder for conspiracy theories". A letter published in The Lancet in July 2021 remarked that the atmosphere of speculation surrounding the issue was of no help in making an objective assessment of the situation. In response to this letter, in a communication published in the same journal, a small group of researchers opposed the idea that scientists should promote unity and called for openness to alternative hypotheses. Despite the unlikelihood of the event, and although definitive answers are likely to take years of research, biosecurity experts have called for a review of global biosecurity policies, citing known gaps in international standards for biosafety.
DiCaprio's second role in 2010 was in Christopher Nolan's critically acclaimed ensemble science-fiction film Inception. Inspired by the experience of lucid dreaming and dream incubation, the film features Dom Cobb (DiCaprio), an "extractor" who enters the dreams of others to obtain information that is otherwise inaccessible. Cobb is promised a chance to regain his old life in exchange for planting an idea in a corporate target's mind. DiCaprio was fascinated with the idea of a "dream-heist" and the potential for his character to manipulate his dreamworld and impact his real life. Made on a budget of $160 million, the film grossed $836 million worldwide to become DiCaprio's second highest-grossing film. To star in this film, DiCaprio agreed to a pay cut from his $20 million fee and opted for a share in first-dollar gross points, which entitled him to a percentage of the cinema ticket sales. The risk proved fruitful, as DiCaprio earned $50 million from the film, becoming his highest payday yet. DiCaprio starred as J. Edgar Hoover in Clint Eastwood's J. Edgar (2011). A biopic about Hoover, the film focuses on his career as an FBI director, including an examination of his private life as an alleged closeted homosexual. Critics felt that the film lacked coherence overall but commended DiCaprio's performance. Roger Ebert praised DiCaprio's ability to bring depth and nuance to the character, suggesting that his performance conveyed aspects of Hoover's personality that were possibly even unknown to the man himself.
ECU Health (formerly Vidant Health) is a not-for-profit, 1,447-bed hospital system that serves more than 1.4 million people in 29 Eastern North Carolina counties. The health system is made up of nine hospitals and more than 12,000 employees. ECU Health also includes wellness centers, home health and hospice services, a dedicated children's hospital, rehab facilities, pain management and wound healing centers and specialized cancer care. Their flagship hospital, ECU Health Medical Center, is a level I trauma center and serves as the teaching hospital for the Brody School of Medicine at East Carolina University in Greenville. Its smaller, community-based hospitals serve as patient feeders to the main hospital. The main hospital has shuttered services at these facilities only to reroute state licenses and permits back to the main hospital. ECU Health is the largest private employer in Eastern North Carolina. All nine ECU Health hospitals have achieved The Gold Seal of Approval for quality care by The Joint Commission, the leading accreditor of healthcare organizations in America. In 2002, the organization implemented a program in which diabetes educators regularly visit rural clinics to improve glycemic control in African-American patients. ECU Health changed their name from University Health Systems of Eastern Carolina in January 2012 to Vidant Health. On January 3, 2022, Vidant Health announced that they would be rebranding as ECU Health. In the announcement, they indicated that it would take several months for the branding to be noticeable to the public.
Sources: en.wikipedia.org
=== Other sources === Various cytochrome P450 enzymes (e.g. CYP1A1, CYP1A2, CYP1B1, CYP2E1, CYP2S1, and CYP3A4) metabolize PGG2 and PGH2 to 12-HHT and MDA. While the latter studies were conducted using recombinant cytochrome enzymes or sub-fractions of disrupted cells, the human monocyte, a form of blood circulating leukocyte, increases its expression of CYP2S1 when forced to differentiate into a macrophage phenotype by interferon gamma or lipopolysaccharide (i.e. endotoxin); associated with these changes, the differentiated macrophage metabolized arachidonic acid to 12-HHT by a CYP2S1-dependent mechanism. Future studies, therefore may show that cytochromes are responsible for 12-HHT and MDA production in vivo. PGH2, particularly in the presence of ferrous iron (FeII), ferric iron (FeIII), or hemin, rearranges non-enzymatically to a mixture of 12-HHT and 12-HHT's 8-cis isomer, i.e., 12-(S)-hydroxy-5Z,8Z,10E-heptadecatrienoic acid. This non-enzymatic pathway may explain findings that cells can make 12-HHT in excess of TXA2 and also in the absence of active cycloxygenase and/or thromboxane synthase enzymes.
=== Low-profile chains === Low-profile chains are chains with low teeth and safety elements between teeth. These chains are used on consumer and small professional saws for non-experienced operators. These chains are more insensitive against dirt, but require more frequent sharpening.
Psychologist Jean Twenge and her colleagues found that this growth of mental health issues was associated with spending more time in front of a screen. It is not clear, however, whether depression causes a teenager to spend more time online or the other way around. Teens who spent more time online were more likely to not have enough sleep, a major predictor of depression. By the mid-2020s, however, the growth of depression and anxiety among young Americans has stalled or slightly reversed, though the reasons remain poorly understood. In its analysis of data from the late 2010s, the American Academy of Pediatrics found that just under half of Americans aged six to seventeen slept for nine hours on most days. Compared to those who did not get enough sleep, those who did were more curious, more likely to finish their homework, and more invested in their education. The risk factors associated with sleep deprivation among children to be the low educational attainment of parents or caregivers, being from families living below the federal poverty line, higher digital media usage, more negative childhood experiences, and mental illnesses. Sleep deprivation is also linked to reduced performance in school and obesity. American teenagers share a common habit of having their smartphones on at night, at the expense of the quality of their own sleep. There has been some evidence that COVID-19 lockdowns have accelerated the aging of adolescent brains (as measured by cortical thinning), especially among girls.
Sources: en.wikipedia.org
It is a synthetic cyclic peptide designed as an analog of alpha-melanocyte-stimulating hormone. It acts on melanocortin receptors and is best known from research into pigmentation. It is not an approved pharmaceutical product.
No regulatory agency has approved it for any indication. It is encountered as a research chemical sold outside pharmaceutical supply chains. Products marketed this way are not subject to the manufacturing and labeling requirements that apply to approved drugs.
Reports describe increased skin pigmentation as well as side effects such as nausea, flushing, and changes to existing moles. Much of the evidence comes from small studies and case reports rather than large trials. The long-term safety profile is therefore uncertain.
No. No major regulatory agency has granted a marketing authorisation for melanotan II as a medicine. Products sold under this name are generally presented as laboratory reagents and are not subject to the batch-release testing applied to approved drugs.